The Latest Breaking News from Disease

ESSA Pharma Inc (NASDAQ:EPIX) presented clinical results from the Phase 1a dose-escalation study of EPI-7386 as a monotherapy for metastatic castration-resistant prostate cancer (mCRPC) resistant to current standard-of-care therapies.  The initial data from 36 patients demonstrate that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily…

Staying active is the simplest way to reduce your chances of heart disease and obesity, as well as a myriad of other health conditions. Walking is one of the easiest activities we do - here's how to make it a calorie-burner.

The Public Health Ministry will declare the country to be in a post-pandemic Covid-19 stage on Friday, as the disease will likely cause only small and medium clusters from now.

None of the patients in the cancer ward have developed severe COVID-19 disease

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

The monkeypox test uses a small drop of finger-prick blood.

French people should start wearing masks again in crowded areas, especially in public transport, as France has to deal with a new wave of COVID-19 infections fuelled by new variants of the disease, Health Minister Brigitte Bourguignon said on Monday.

Heart and circulatory diseases cause a quarter of all UK deaths

According to a Reuters report, U.S. District Judge Jesse Furman in Manhattan refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co (NYSE:BMY) of delaying its Breyanzi cancer drug to avoid payments to former Celgene shareholders. The judge rejected Bristol Myers' claim that it was never properly notified about its alleged default…